Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 1/20 | 0.64 |
| ▸ | PPARG | P37231 | 17/20 | 0.58 |
| ▸ | PPARA | Q07869 | 17/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.57 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3286675 | 0.92 | FFAR1 (0.63) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL3287513 | 0.90 | KDR (0.50) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL3284433 | 0.86 | FFAR1 (0.52) | KDRPPARGPPARAFFAR1 | |
| SCHEMBL3280172 | 0.84 | PPARG (0.62) | PPARGPPARA | |
| SCHEMBL4031039 | 0.83 | KDR (0.74) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5202291 | 0.82 | KDR (0.68) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL4029683 | 0.82 | KDR (0.70) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL4031041 | 0.81 | KDR (0.67) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL27650834 | 0.81 | KDR (0.74) | KDRPPARGPPARACYP2C9KCNH2 | |
| SCHEMBL14514345 | 0.80 | KDR (0.78) | KDRPPARGPPARACYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | claimed |
| JP-2007505857-A | — | — | 2007-03-15 | — | — | JP | claimed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | claimed |
| EP-1664002-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-06-07 | — | — | EP | claimed |
| WO-2005026134-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | claimed |
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | disclosed |
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | disclosed |
| US-20100152255-A1 | Organic Compounds | DAMON ROBERT EDSON | 2010-06-17 | — | — | US | disclosed |
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| US-7700637-B2 | Organic compounds | NOVARTIS AG (CH) | 2010-04-20 | — | — | US | disclosed |
| CN-100482649-C | Organic compounds | NOVARTIS AG (CH) | 2009-04-29 | — | — | CN | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | NOVARTIS AG (CH) | 2007-01-04 | — | — | US | disclosed |
| EP-1664002-A1 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2006-06-07 | — | — | EP | disclosed |
| WO-2005026134-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152255-A1 | Organic Compounds | PPARG, FABP2, PPARA | KDR 649/4885PPARG 1/4885PPARA 3/4885 |
| US-20070004704-A1 | Such as 6-Methyl-2-[4-(5-methyl-2-phenyl-oxazol-4-ylmethoxy)-benzenesulfonylamino]-benzoic acid which binds Peroxisome Proliferator-Activated Receptors; conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes, and Syndrome X | PPARG, GPR119, PPARA | KDR 847/4885PPARG 1/4885PPARA 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.